Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells ; volume:22 ; number:1 ; day:29 ; month:9 ; year:2022 ; pages:1-12 ; date:12.2022
BMC cancer ; 22, Heft 1 (29.9.2022), 1-12, 12.2022
- Creator
-
Olokpa, Emuejevoke
Mandape, Sammed N.
Pratap, Siddharth
Stewart, La Monica V.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-10115-3
- URN
-
urn:nbn:de:101:1-2022121709123275789563
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Olokpa, Emuejevoke
- Mandape, Sammed N.
- Pratap, Siddharth
- Stewart, La Monica V.
- SpringerLink (Online service)
Other Objects (12)
Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Glucocorticoid receptor-induced non-muscle caldesmon regulates metastasis in castration-resistant prostate cancer
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Ailanthone: a new potential drug for castration-resistant prostate cancer